Eli Lilly (LLY) Other Accumulated Expenses (2009 - 2026)

Eli Lilly has reported Other Accumulated Expenses for 18 years, with the latest figure at $8.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 130.75% year-over-year to $8.7 billion; the trailing twelve-month figure through Mar 2026 stood at $8.7 billion (up 130.75% YoY), and the FY2025 full-year result was $8.5 billion, up 32.2% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $8.7 billion, up from $8.5 billion in the prior quarter.
• The five-year high for Other Accumulated Expenses was $8.7 billion in Q1 2026, with the low at $2.0 billion in Q3 2022.
• Historically, Other Accumulated Expenses has averaged $4.2 billion across 5 years, with a median of $3.8 billion in 2025.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses decreased 23.67% — and 2026, when it soared 130.75%.
• Eli Lilly's Other Accumulated Expenses stood at $2.8 billion in 2022, then gained by 15.32% to $3.3 billion in 2023, then surged by 94.95% to $6.4 billion in 2024, then soared by 32.2% to $8.5 billion in 2025, then grew by 2.86% to $8.7 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $8.7 billion (Q1 2026), $8.5 billion (Q4 2025), and $5.2 billion (Q3 2025), per Business Quant data.